26 июл. 2024 г. · Long-acting injectable lenacapavir as pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV acquisition in women.

Lenacapavir (brand name: Sunlenca) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in ...

15 февр. 2023 г. · Lenacapavir injection is used along with other medications to treat human immunodeficiency virus type 1 (HIV-1) in certain adults.

Lenacapavir, sold under the brand name Sunlenca, is an antiretroviral medication used to treat HIV/AIDS. It is taken by mouth or by subcutaneous injection.

26 сент. 2024 г. · LEN, an HIV-1 capsid inhibitor delivered by subcutaneous injection twice a year, was shown to be highly effective in preventing HIV among cisgender men, ...

SUNLENCA® (lenacapavir) is an injectable prescription medicine used to treat HIV-1, together with other HIV-1 medicines, in adults with HIV-1 that meet ...

SUNLENCA Is a Long-acting SC Injectable Administered Only Twice a Year · Maintenance injections are given once every 26 weeks (±2 weeks) from the date of ...

31 янв. 2024 г. · Lenacapavir injection is used together with other medicines to treat human immunodeficiency virus (HIV) infection in patients who have previously received ...

Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it ...

Injectable lenacapavir (LEN) is an investigational antiretroviral (ARV) drug that is being studied as a potential PrEP product.